To make medicines more affordable, President Trump insists that “foreign freeloading” must end.

He complains that other wealthy countries often pay less for the same drugs while the U.S. is unfairly forced to shoulder higher costs of underwriting pharma R&D. So the administration is pushing a plan to cap what Medicare pays for certain medicines based on prices charged elsewhere. The idea is for Medicare to narrow that gap — and eventually lower costs by 30 percent.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy